Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levothyroxine TSH suppression to prevent radiation-induced hypothyroidism
2021-001385-38Phase 3Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levothyroxine sodium in radiation-induced hypothyroidism (RIHT) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Hypothyroidism-free survival at 3 years. Started Aug 2021; status: active.
02
Drugs
levothyroxine sodium
03
Conditions
radiation-induced hypothyroidism (RIHT)
Beyond the preview
Go deeper on 2021-001385-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001385-38.